Trial Profile
A Study on the 24-hour Intraocular Pressure Profile of the 0.0015% Tafluprost Ophthalmic Solution in Patients with Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma or Ocular Hypertension
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2016
Price :
$35
*
At a glance
- Drugs Tafluprost (Primary)
- Indications Angle-closure glaucoma; Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
- 22 Apr 2016 Phase of the trial changed from phase I to phase IV as per Chinese Clinical Trial Register
- 22 Apr 2016 Status changed from not yet recruiting to recruiting as per Chinese Clinical Trial Register.
- 16 Jun 2014 New trial record